Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT01615627

Hypotonic Treprostinil Subcutaneous Infusion for Control of Treprostinil Related Site Pain

Status
Withdrawn
Phase
Phase 4
Study type
Interventional
Enrollment
0 (actual)
Sponsor
Jewish General Hospital · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The investigators will test whether hypotonic (diluted) remodulin solution causes less pain than the eutonic (undiluted) solution supplied by the manufacturer.

Conditions

Interventions

TypeNameDescription
DRUGHypotonicTreprostinil SolutionHypotonic Treprostinil Solution
DRUGEutonic Treprostinil SolutionEutonic Treprostinil Solution

Timeline

Start date
2012-07-01
Primary completion
2019-02-28
Completion
2019-02-28
First posted
2012-06-08
Last updated
2020-03-03

Locations

1 site across 1 country: Canada

Source: ClinicalTrials.gov record NCT01615627. Inclusion in this directory is not an endorsement.

Hypotonic Treprostinil Subcutaneous Infusion for Control of Treprostinil Related Site Pain (NCT01615627) · Clinical Trials Directory